CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

A new injectable weight loss treatment from the maker of Ozempic and Wegovy delivered 23% weight loss in trials, according to ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...